twentyfirst
centuri
experienc
emerg
epidem
three
previous
unidentifi
coronavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
novel
coronaviru
later
offici
name
late
decemb
belong
coronavirida
famili
virus
possess
positivesens
singlestrand
rna
genom
similar
rna
virus
famili
character
signific
genet
variabl
high
recombin
rate
enabl
easili
distribut
among
human
anim
worldwid
result
numer
coronavirus
exist
within
human
anim
popul
without
caus
lifethreaten
diseas
howev
occasion
genet
recombin
virus
within
random
intermedi
host
produc
contagi
strain
highli
pathogen
human
wherea
genet
structur
relat
sarscov
becom
increasingli
clear
uniqu
featur
contribut
rapid
spread
around
globe
sinc
current
effect
treatment
avail
coronaviru
infect
signific
effort
made
develop
vaccin
therapeut
drug
preclin
evid
proven
potenti
sever
countermeasur
yet
larg
scale
trial
still
need
review
current
understand
epidemiolog
clinic
featur
well
uniqu
contagi
characterist
differ
sarscov
merscov
provid
essenti
inform
adjust
respons
pandem
also
summar
stateoftheart
innov
target
biolog
patholog
point
view
april
total
case
occur
least
countri
territori
report
approxim
fatal
rate
prior
overview
china
includ
confirm
suspect
asymptomat
patient
reveal
sever
import
epidemiolog
featur
gener
major
confirm
case
age
yearsold
among
death
major
among
patient
year
age
age
group
character
highest
fatal
rate
among
age
group
ref
rel
fewer
case
report
among
young
children
yearsold
ref
male
affect
diseas
maletofemal
ratio
vari
focus
differ
popul
scale
china
overal
hubei
provinc
wuhan
citi
fortun
affect
patient
pneumonia
present
mild
moreov
pathogen
extraordinarili
contagi
death
occur
mild
even
sever
case
expect
fatal
rate
reach
among
patient
classifi
critic
case
usual
symptom
includ
fever
cough
short
breath
muscl
ach
similar
sar
mer
ref
patient
may
sore
throat
rhinorrhea
headach
confus
day
onset
fever
indic
fever
critic
symptom
initi
manifest
infect
ref
pattern
fever
yet
fulli
understood
small
proport
patient
hemoptysi
number
case
found
rel
asymptomat
ref
patient
may
normal
lower
white
blood
cell
count
lymphopenia
thrombocytopenia
increas
creactiv
protein
level
ref
peopl
fever
upper
respiratori
tract
symptom
leukopenia
lymphopenia
suspect
diseas
especi
patient
travel
histori
endem
area
close
exposur
record
howev
clinic
cours
pneumonia
exhibit
broad
spectrum
sever
progress
pattern
patient
dyspnea
develop
within
median
day
onset
ill
rang
day
other
respiratori
distress
may
absent
ref
around
patient
may
need
admiss
intens
care
unit
sever
ill
patient
may
poor
diseas
cours
rapid
progress
multipl
organ
dysfunct
even
death
short
breath
hypoxemia
quickli
progress
acut
respiratori
distress
syndrom
ard
sever
sepsi
shock
even
multipl
organ
dysfunct
within
one
week
ref
ard
observ
develop
hospit
patient
approxim
day
symptom
onset
global
mortal
rate
reach
approxim
also
worth
note
gastrointestin
symptom
may
caus
direct
viral
damag
intestin
rather
immunopathogen
respons
lung
infect
host
sinc
angiotensinconvert
enzym
main
cellular
receptor
express
human
gastrointestin
epitheli
cell
believ
viral
shed
gastrointestin
tract
transmiss
highli
plausibl
ref
inde
report
rectal
swab
show
posit
result
even
nasopharyng
test
constitut
neg
besid
live
viru
also
detect
stool
sampl
diseas
patient
evid
strongli
indic
stool
contagi
long
time
discharg
patient
base
two
neg
nasopharyng
swab
thu
ad
rectal
swab
discharg
criteria
consid
prevent
nosocomi
commun
spread
asid
gastrointestin
symptom
retrospect
studi
patient
china
report
patient
experienc
hypogeusia
experienc
hyposmia
though
loss
olfact
infect
could
explain
swell
nasal
mucosa
larger
popul
patient
includ
determin
whether
hypogeusia
hyposmia
could
common
neurolog
manifest
nevertheless
hyposmia
hypogeusia
recommend
earli
warn
sign
indic
earli
selfisol
wherea
sever
human
coronavirus
caus
mild
respiratori
diseas
estim
circul
human
popul
centuri
sarscov
merscov
zoonot
transfer
mammalian
speci
last
year
horsesho
bat
natur
reservoir
novel
coronavirus
intermedi
host
transmit
viru
human
identifi
mask
palm
civet
sarscov
dromedari
camel
merscov
tabl
recent
metagenom
studi
detect
similar
coronavirus
malayan
pangolin
mani
javanica
one
speci
presum
smuggl
huanan
wet
market
wuhan
differ
transmiss
pattern
sarscov
merscov
also
indic
specif
intrins
characterist
case
sarscov
merscov
substanti
viru
shed
happen
onset
symptom
therefor
transmiss
mainli
occur
nosocomi
manner
name
infect
patient
sought
medic
help
howev
humantohuman
transmiss
occur
predominantli
commun
famili
member
might
indic
pathogen
could
spread
far
onset
symptom
recent
studi
suggest
halfliv
sarscov
similar
aerosol
median
infecti
period
estim
around
hour
therefor
echo
sarscov
possibl
airborn
transmiss
rule
howev
evid
still
need
addit
preexist
factor
contribut
blind
spot
diseas
control
previou
studi
found
activ
surveil
two
individu
close
contact
histori
confirm
case
show
posit
result
rtpcr
anoth
report
reveal
patient
proven
recov
two
consecut
rtpcr
test
turn
show
posit
result
day
later
patient
continu
asymptomat
peopl
within
close
contact
infect
still
consid
infecti
viral
carrier
conclus
evid
exist
infect
case
contagi
onset
treatment
pneumonia
thu
current
criteria
hospit
discharg
discontinu
quarantin
may
reevalu
order
achiev
intact
protocol
adequ
diseas
control
tabl
compar
differ
featur
sarscov
merscov
sarscov
merscov
belong
coronavirida
famili
famili
virus
contain
rel
larg
singlestrand
positivesens
rna
genom
around
kb
ref
genom
typic
compos
cap
begin
tail
end
total
gene
order
gene
usual
highli
conserv
first
one
replic
transcriptionrel
rest
structur
replic
transcriptionrel
gene
translat
two
larg
nonstructur
polyprotein
two
open
read
frame
ref
two
differ
yet
overlap
open
read
frame
translat
ribosom
frameshift
hand
structur
protein
includ
spike
envelop
e
membran
constitut
viral
coat
nucleocapsid
n
protein
packag
viral
genom
translat
subgenom
rna
protein
undergo
glycosyl
golgi
apparatu
form
glycoprotein
among
structur
protein
import
potenti
therapeut
target
spike
glycoprotein
respons
bind
viru
host
cell
protein
prime
host
cell
proteas
recogn
cellular
receptor
ref
human
serin
proteas
respons
prime
protein
sarscov
angiotensinconvert
enzym
engag
receptor
entri
two
virus
merscov
bind
specif
anoth
receptor
dipeptidyl
peptidas
worth
note
express
level
also
allel
frequenc
vari
among
popul
sever
variant
identifi
correl
diseas
suscept
sequenc
polymorph
hypothes
howev
previou
studi
confirm
case
found
heterogen
among
residu
implic
viral
protein
bind
indic
may
associ
highlyconserv
site
human
genom
indistinguish
suscept
individu
anoth
reason
rapid
spread
across
contin
differ
human
popul
characterist
cellular
receptor
also
explain
pathogenesi
featur
sarscov
report
bind
viral
protein
induc
neg
feedback
loop
ultim
result
downregul
decreas
subsequ
direct
substrat
angiotensin
toward
relat
enzym
ace
increas
ace
activ
consequ
result
elev
level
angiotensin
ii
angiotensin
ii
bind
receptor
pulmonari
vascular
permeabl
increas
recommend
center
diseas
control
prevent
health
care
profession
obtain
specimen
upper
respiratori
tract
either
nasopharyng
oropharyng
lower
respiratori
tract
either
endotrach
tube
bronchoalveolar
lavag
diagnosi
pneumonia
primarili
base
rtpcr
analysi
specimen
rtpcr
unavail
serolog
test
may
also
consid
current
us
food
drug
administr
fda
approv
commerci
test
system
roch
qualit
test
requir
sampl
nasopharyng
oropharyng
swab
take
h
yield
result
base
rtpcr
methodolog
coba
test
dual
target
assay
detect
specif
rna
well
highli
conserv
fragment
e
gene
invari
member
sarbecoviru
subgenu
assay
fullprocess
neg
control
posit
control
intern
control
ensur
specif
accuraci
march
fda
grant
anoth
emerg
use
author
xpress
cepheid
inc
usa
also
qualit
test
claim
yield
result
within
min
util
sampl
nasopharyng
swab
nasal
wash
aspir
specimen
highlight
handsoff
autom
sampl
process
result
view
posit
one
target
gene
present
detect
current
screen
method
reli
presenc
abund
viral
genom
site
sampl
collect
studi
demonstr
level
igm
antibodi
high
symptomat
subclin
patient
day
onset
ill
thu
propos
igm
elisa
assay
combin
pcr
enhanc
detect
sensit
current
specif
treatment
pneumonia
clinic
manag
emphas
import
support
care
prevent
complic
nosocomi
transmiss
patient
experi
respiratori
distress
oxygen
given
immedi
howev
sign
tissu
hypoperfus
fluid
resuscit
rel
conserv
may
result
lung
edema
worsen
oxygen
statu
concept
particularli
import
treatment
sever
acut
respiratori
infect
could
shorten
durat
ventil
system
corticosteroid
recommend
either
consid
potenti
delay
viral
clearanc
nevertheless
except
could
made
corticosteroid
indic
reason
standard
precaut
includ
respiratori
eye
protect
recommend
healthcar
profession
care
patient
known
suspect
pneumonia
remov
droplet
precaut
consid
two
consecut
rtpcr
obtain
least
h
apart
clinic
recov
patient
show
neg
result
howev
base
previou
discuss
even
two
set
neg
test
still
possibl
patient
becom
viral
carrier
later
therebi
suggest
decis
remov
precaut
base
laboratori
radiolog
clinic
evid
also
profession
assess
clinician
special
healthcar
personnel
remdesivir
far
promis
drug
exhibit
broadspectrum
antivir
activ
rna
virus
prodrug
whose
structur
resembl
adenosin
ref
therefor
incorpor
nascent
viral
rna
inhibit
rnadepend
rna
polymeras
result
prematur
termin
viral
rna
chain
consequ
halt
replic
viral
genom
remdesivir
origin
develop
gilead
scienc
usa
ebola
viru
undergon
clinic
trial
recent
ebola
outbreak
democrat
republ
congo
although
shown
effect
ebola
trial
prove
safeti
human
allow
enter
clinic
trial
immedi
condit
emerg
importantli
previous
shown
exhibit
antivir
activ
differ
coronavirus
includ
sarscov
merscov
vitro
vivo
recent
vitro
studi
remdesivir
also
shown
inhibit
report
case
report
first
patient
usa
remdesivir
use
day
hospit
without
notic
advers
effect
patient
condit
improv
day
remdesivir
test
multipl
trial
differ
countri
includ
two
random
phase
iii
trial
china
expect
complet
aprilmay
similar
remdesivir
favipiravir
develop
toyama
chemic
divis
fujifilm
japan
function
inhibitor
rnadepend
rna
polymeras
structur
resembl
endogen
guanin
competit
inhibit
efficaci
viral
replic
huge
reduc
although
approv
treatment
influenza
less
preclin
support
establish
favipiravir
treat
compar
remdesivir
nevertheless
patient
recruit
evalu
efficaci
favipiravir
plu
base
expect
synergist
effect
viral
inhibit
immun
enhanc
inde
march
favipiravir
approv
nation
medic
product
administr
china
first
drug
china
clinic
trial
demonstr
efficaci
minim
side
effect
ivermectin
fdaapprov
antiparasit
agent
also
proven
exert
antivir
activ
toward
human
immunodefici
viru
hiv
dengu
viru
dissoci
preform
heterodim
respons
nuclear
transport
viral
protein
cargo
nuclear
transport
viral
protein
essenti
replic
cycl
inhibit
host
antivir
respons
target
nuclear
transport
process
may
viabl
therapeut
approach
toward
rna
virus
recent
vivo
studi
proven
ivermectin
capabl
reduc
viral
rna
h
infect
establish
safeti
profil
antiparasit
use
next
step
prove
ivermectin
efficaci
treat
involv
trial
figur
adequ
dose
aspartyl
proteas
enzym
encod
pol
gene
human
immunodefici
viru
hiv
cleav
precursor
polypeptid
hiv
thu
play
essenti
role
replic
cycl
hiv
proteas
inhibitor
lopinavir
ritonavir
therefor
use
combin
hiv
therapeut
drug
although
coronavirus
encod
differ
enzymat
class
proteas
cystein
proteas
theoret
evid
exist
lopinavir
ritonavir
also
inhibit
coronavir
proteas
importantli
number
clinic
anim
vitro
model
studi
perform
sar
mer
prove
effect
respect
virus
lopinavirritonavir
combin
engag
clinic
trial
patient
mild
moder
howev
show
littl
benefit
improv
clinic
outcom
anoth
trial
perform
patient
sever
benefit
lopinavirritonavir
beyond
standard
care
observ
solubl
recombin
human
angiotensinconvert
enzym
expect
block
entri
block
protein
interact
cellular
inde
recent
studi
report
could
inhibit
replic
cellular
embryon
stem
cellderiv
organoid
factor
time
believ
administr
recombin
human
angiotensinconvert
enzym
decreas
serum
level
angiotensin
ii
direct
substrat
away
relat
enzym
ace
like
mention
earlier
could
prevent
activ
receptor
therebi
preserv
pulmonari
vascular
integr
prevent
ard
origin
develop
apeiron
biolog
alreadi
undergon
phase
ii
trial
ard
small
pilot
studi
china
evalu
biolog
physiolog
role
pneumonia
especi
treatment
ard
later
apeiron
biolog
initi
placebo
control
doubl
blind
doseescal
studi
access
safeti
toler
intraven
believ
measur
plasma
level
angiotensin
ii
angiotensin
bioproduct
interf
potenti
drug
biolog
physiolog
role
pneumonia
could
evalu
wellknown
antimalari
antiautoimmun
agent
hydroxychloroquin
also
block
viru
infect
increas
endosom
ph
requir
membran
fusion
viru
host
cell
moreov
shown
specif
inhibit
replic
sarscov
interf
glycosyl
cellular
receptor
recent
vitro
test
reveal
abil
effect
reduc
viral
copi
number
therefor
number
clinic
trial
quickli
conduct
china
demonstr
hydroxychloroquin
variou
degre
effect
treatment
pneumonia
similarli
small
openlabel
nonrandom
clinic
trial
franc
hydroxychloroquin
demonstr
posit
effect
combin
azithromycin
wake
evid
us
fda
issu
emerg
use
author
use
hydroxychloroquin
treat
usa
noteworthi
latest
studi
found
evid
clinic
benefit
combin
hydroxychloroquin
azithromycin
treatment
patient
sever
thu
larger
random
control
trial
need
evalu
approv
russia
china
arbidol
entri
inhibitor
influenza
virus
arbovirus
target
hemagglutinin
ha
major
glycoprotein
surfac
influenza
viru
arbidol
prevent
fusion
viral
membran
endosom
endocytosi
current
undergo
trial
singl
agent
random
clinic
trial
aim
compar
arbidol
favipiravir
latter
demonstr
far
superior
treatment
outcom
highest
mortal
rate
inflict
observ
among
elderli
patient
may
explain
weaken
immun
system
age
therefor
approach
aim
boost
innat
antivir
immun
respons
great
potenti
natur
killer
nk
cell
constitut
import
compon
innat
immun
system
ensur
rapid
respons
viral
infect
previou
studi
shown
pulmonari
migrat
nk
cell
macrophag
play
signific
role
clearanc
sarscov
innat
respons
without
assist
cell
antibodi
abl
control
sarscov
infect
increas
product
cytokin
chemokin
whether
addit
nk
cell
could
help
reach
viral
clearanc
pneumonia
phase
trial
china
estim
complet
end
sever
compani
aim
repurpos
anticanc
nkbase
product
treat
among
jointli
develop
product
green
cross
labcel
south
korea
kleo
pharmaceut
us
usabas
compani
celular
develop
placenta
haematopoet
stem
cellderiv
nk
cell
type
interferon
secret
virusinfect
cell
use
alon
combin
drug
exert
broadspectrum
antivir
effect
hcv
respiratori
syncyti
viru
sarscov
merscov
trial
focus
safeti
efficaci
treat
pneumonia
mesenchym
stem
cell
msc
proven
exert
antiinflammatori
function
decreas
proinflammatori
cytokin
produc
paracrin
factor
repair
tissu
preclin
evid
also
shown
msc
abl
restor
endotheli
permeabl
also
reduc
inflammatori
infiltr
immunomodul
effect
msc
proven
avian
influenza
virus
role
pneumonia
still
evalu
present
msc
umbil
cord
dental
pulp
test
intraven
immunoglobulin
ivig
wide
appli
field
neurolog
dermatolog
rheumatolog
dosedepend
manner
ivig
exert
divers
effect
immun
system
gener
low
dose
ivig
use
replac
therapi
antibodi
defici
higher
dose
ivig
exhibit
immunomodulatori
function
suppress
inflammatori
cell
prolifer
inhibit
phagocytosi
interf
antibodydepend
cytotox
current
trial
focu
supplementari
effect
low
dose
ivig
day
humor
immun
respons
mediat
antibodi
crucial
prevent
viral
infect
therefor
develop
specif
surfac
epitopetarget
neutral
antibodi
longterm
albeit
specif
approach
target
abcellera
canada
eli
lilli
compani
usa
codevelop
function
antibodi
could
neutral
infect
patient
purpos
screen
million
immun
cell
one
first
us
patient
recov
identifi
potenti
antibodi
sequenc
current
undergo
screen
find
effect
one
wherea
approach
timeconsum
effortdemand
encourag
success
appli
manufactur
specif
function
antibodi
west
nile
viru
vir
biotechnolog
inc
immunoprecis
mount
sinai
health
system
harbour
biom
hbm
also
screen
find
monoclon
antibodi
tackl
although
still
preclin
stage
elig
candid
expect
exert
prophylact
therapeut
effect
complement
activ
demonstr
acut
lung
injuri
bioactiv
molecul
cleav
respons
full
develop
tissu
injuri
role
includ
recruit
neutrophil
tlymphocyt
increas
pulmonari
vascular
permeabl
also
prove
treatment
could
reduc
lung
injuri
decreas
vascular
leakag
neutrophil
influx
alveolar
space
henc
launch
beij
defengrei
biotechnolog
co
produc
beij
staidson
biopharma
inflarx
monoclon
antibodi
target
foundat
inflammatori
respons
expect
attenu
level
lung
injuri
caus
interleukin
il
import
proinflammatori
cytokin
human
bodi
specif
predict
factor
poor
prognosi
patient
ard
recent
also
report
elev
strongli
associ
need
mechan
ventil
classic
pathway
signal
occur
receptor
express
neutrophil
monocyt
macrophag
leukocyt
popul
besid
bind
membranebound
receptor
also
bind
solubl
form
receptor
creat
proteolyt
cleavag
altern
splice
mrna
elev
level
circul
associ
faster
declin
lung
elast
sever
bronchoalveolar
inflamm
henc
specif
blockad
signal
pathway
repres
promis
approach
attenu
inflammationassoci
damag
moreov
report
tuberculosi
model
mice
blockad
lead
increas
bacteri
burden
lung
contrari
neutral
antibodi
result
signific
increas
mycobacteri
coloni
unit
eusa
pharma
initi
studi
evalu
effect
siltuximab
monoclonc
antibodi
treat
patient
ard
hand
tiziana
life
scienc
develop
receptor
antibodi
treat
diseas
anoth
perspect
compani
believ
administr
antibodi
could
result
inhibit
downstream
signal
either
membran
bound
solubl
receptor
reduct
circul
level
regeneron
pharmaceut
sanofi
also
conduct
phase
ii
phase
iii
trial
kevzara
sarilumab
receptor
antagonist
sever
critic
patient
though
kevzara
proven
efficaci
treat
arthriti
efficaci
treat
still
unknown
recent
thalidomid
reemerg
antiangiogen
antiinflammatori
antifibrot
agent
decreas
synthesi
tnfalpha
thalidomid
use
treatment
multipl
inflammatori
diseas
crohn
diseas
behcet
diseas
addit
preclin
studi
prove
thalidomid
effect
treat
mice
reduc
infiltr
inflammatori
cell
product
proinflammatori
cytokin
current
studi
focus
immunomodulatori
effect
could
lessen
lung
injuri
caus
excess
immun
respons
mention
earlier
system
glucocorticoid
current
contraind
infect
may
prolong
viral
clearanc
howev
also
known
underli
pathogenesi
pneumonia
compos
direct
damag
caus
viru
excess
immun
respons
host
thu
whether
methylprednisolon
administr
would
help
suppress
unwant
immun
reaction
controversi
therefor
studi
initi
explor
effect
safeti
fingolimod
oral
immunomodul
agent
primarili
use
treat
refractori
multipl
sclerosi
structur
resembl
lipid
fingolimod
act
highli
potent
function
antagonist
receptor
lymph
node
cell
effect
bind
receptor
intern
lymph
node
cell
subsequ
sequest
decreas
pulmonari
influx
lymphocyt
anoth
approach
attenu
uncontrol
immunopathogenesi
elev
vascular
endotheli
growth
factor
vegf
level
observ
patient
acut
respiratori
distress
syndrom
vegf
function
mediat
induc
endotheli
injuri
increas
microvascular
permeabl
bevacizumab
recombin
human
monoclon
antibodi
wide
use
treat
multipl
type
cancer
capabl
block
angiogenesi
specif
bind
vegf
ongo
trial
evalu
effect
bevacizumab
uniqu
approach
treat
infect
earli
januari
soon
outbreak
pneumonia
genom
sequenc
moderna
synthet
strand
mrna
encod
prefusionstabil
viral
spike
protein
intramuscular
inject
human
bodi
expect
elicit
antivir
respons
specif
toward
spike
protein
besid
unlik
convent
vaccin
either
made
inactiv
pathogen
small
subunit
live
pathogen
synthesi
lipid
nanoparticleencapsul
mrna
vaccin
requir
viru
therefor
rel
safe
readi
test
prove
safe
human
pass
phase
trial
success
evalu
efficaci
carri
immedi
dna
vaccin
candid
creat
inovio
pharmaceut
like
moderna
also
genet
vaccin
deliv
human
cell
translat
protein
elicit
immun
respons
compar
convent
vaccin
genet
vaccin
requir
lower
cost
product
easier
way
purif
simpl
structur
nucleic
acid
also
obviat
risk
incorrect
fold
could
occur
recombin
proteinbas
vaccin
howev
amount
plasmid
deliv
adequ
interv
rout
administr
factor
may
influenc
immunogen
genet
vaccin
vaccin
creat
univers
oxford
compos
nonrepl
adenoviru
vector
genet
sequenc
protein
enter
phase
iii
clinic
trial
nonrepl
natur
adenoviru
host
make
rel
safe
children
individu
underli
diseas
besid
adenovirusbas
vector
character
broad
rang
tissu
tropism
cover
respiratori
gastrointestin
epithelium
two
main
site
express
receptor
howev
possibl
domin
immunogen
toward
vector
gene
rather
transgen
alway
consid
envelop
virus
requir
fusion
viral
membran
host
cell
membran
infect
process
involv
conform
chang
viral
glycoprotein
prefus
form
postfus
form
although
prefus
glycoprotein
rel
unstabl
still
abl
elicit
strong
immun
respons
thu
univers
queensland
develop
stabil
subunit
vaccin
base
molecular
clamp
technolog
would
allow
recombin
viral
protein
stabli
remain
prefus
form
previous
appli
influenza
viru
ebola
viru
molecular
clamp
vaccin
prove
capac
induc
product
neutral
antibodi
also
report
potent
two
week
nanoparticlebas
platform
repres
altern
strategi
incorpor
antigen
encapsul
coval
function
nanoparticl
conjug
antigen
epitop
mimic
virus
provok
antigenspecif
lymphocyt
prolifer
well
cytokin
product
addit
mucos
vaccin
intranas
oral
spray
stimul
immun
reaction
mucos
surfac
also
provok
system
respons
demonstr
potenti
nanoparticlebas
vaccin
protect
human
respiratori
virus
caus
system
symptom
novavax
inc
produc
nanoparticlebas
vaccin
use
antigen
deriv
coronaviru
protein
protein
stabli
express
baculoviru
system
product
anticip
enter
phase
trial
summer
base
knowledg
antigenspecif
cell
abl
erad
cancer
cell
well
viral
infect
gener
larg
amount
cell
viral
antigen
specif
time
manner
may
well
help
us
withstand
invas
effici
method
produc
massiv
amount
cell
includ
appropri
antigenpres
cell
activ
effector
cell
differenti
prolifer
correspond
effector
cytotox
cell
henc
genet
modifi
artifici
antigenpres
cell
aapc
express
conserv
domain
viral
structur
protein
deliv
lentiviru
vector
suppos
evok
cell
human
bodi
lead
differenti
prolifer
trial
evalu
safeti
immunogen
aapc
alon
combin
antigenspecif
cytotox
cell
articl
present
overview
current
state
knowledg
pandem
addit
overview
epidemiolog
clinic
radiolog
featur
figur
also
summar
possibl
therapeut
option
current
investig
futur
outlook
diseas
also
specul
sever
mechan
contribut
novel
profil
pneumonia
includ
high
transmiss
caus
unvari
structur
viral
bind
site
among
differ
popul
uniqu
progress
pattern
patient
could
asymptomat
yet
present
posit
radiograph
laboratori
find
summar
current
clinic
trial
rapidli
initi
upon
onset
pandem
emerg
current
undergo
april
base
repurpos
therapeut
agent
previous
design
applic
agent
divid
two
broad
categori
directli
target
viru
replic
cycl
base
immunotherapi
approach
either
aim
boost
innat
antivir
immun
respons
allevi
damag
induc
dysregul
inflammatori
respons
wherea
vaccin
therapeut
antibodi
aim
specif
target
also
test
solut
longterm
requir
thorough
test
safeti
hand
drug
repurpos
happen
practic
approach
rapid
respons
measur
emerg
pandem
agent
alreadi
test
safeti
demonstr
action
virus
includ
relat
sarscov
merscov
drug
target
differ
viral
infect
respons
pathway
directli
interfer
viru
replic
cycl
summar
figur
alreadi
demonstr
promis
result
initi
clinic
trial
perform
wake
pandem
approv
wider
use
promis
exampl
includ
favipiravir
influenza
drug
interfer
viral
replic
hydroxychloroquin
repurpos
antimalari
drug
interfer
viru
endosom
entri
pathway
pose
signific
challeng
toward
public
health
system
exist
antivir
strategi
undoubtedli
grab
globe
attent
begin
believ
may
trigger
systemat
approach
prepar
advanc
potenti
futur
pandem
era
big
data
systemat
approach
identifi
potenti
agent
drug
repurpos
appli
noteworthi
recent
studi
zhou
et
al
wherebi
integr
analysi
interactom
network
associ
human
coronavirus
drug
target
compon
network
appli
reveal
novel
candid
drug
repurpos
believ
comput
techniqu
combin
followup
experiment
studi
aim
test
comput
predict
antivir
agent
help
us
wider
arsen
potenti
repurpos
drug
case
futur
viru
outbreak
